Renal Dysfunction

Renal dysfunction is a myeloma-defining event characterized by elevated serum creatinine or impaired creatinine clearance.1
It is caused by overproduction of monoclonal light chains, which damages the kidneys.2,3
Prevalence3,4
- Between 15% and 40% of patients experience this complication due to hypercalcemia and protein deposition
- Renal impairment is increasingly reversible due to more effective antimyeloma therapies and improvements in supportive care
Common Signs and Symptoms3
- Anemia
- Fatigue
- Malaise
- Fluid and electrolyte imbalances
- Decreased urination
Assessment
Serum creatinine
- Defined as >2 mg/dL (>177 μmol/L)1
Creatinine clearance
- Defined as <40 mL/min (volume of plasma cleared of creatinine)1
- Provides estimation of glomerular filtration rate1
- Can be measured by 24-hour urine collection3
- Can be determined via the Cockcroft-Gault equation3
Management3
- Evaluate associated signs and symptoms
- Review medications for aggravating therapies
- Monitor aggravating health conditions, such as diabetes or hypertension
- Assess light-chain proteinuria to help distinguish between nonparaprotein-related causes and light-chain–induced renal impairment
For Your Patients3
- Explain the symptoms of renal dysfunction and the importance of reporting them
- Encourage appropriate patients to engage in:
- Exercise
- Weight control
- Smoking cessation
- Adherence to blood pressure and blood sugar medications
- Discuss how renal function may affect the ability to receive certain antimyeloma treatments
References:
- Rajkumar SV, Dimopoulos MA, Palumbo A, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15(12):e538-e548.
- Tricot G. Clinical manifestations. In: Hoffman R, Furie B, Benz EJ, McGlave P, Silberstein LE, Shattil SJ. Hematology: Basic Principles and Practice. 5th ed. New York, NY: Churchill Livingstone; 2008.
- Faiman B, Doss D, Colson K, et al; and the International Myeloma Foundation Nurse Leadership Board. Renal, GI, and peripheral nerves; evidence-based recommendations for the management of symptoms and care for patients with multiple myeloma. Clin J Oncol Nurs. 2017;21(5 suppl):19-36.
- Dimopoulos DA, Terpos E, Chanan-Khan A, et al. Renal impairment in patients with multiple myeloma: a consensus statement on behalf of the International Myeloma Working Group.
J Clin Oncol. 2010;28(33):4976-4984.